{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:35:25Z","timestamp":1776206125570,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,1,8]],"date-time":"2022-01-08T07:21:53Z","timestamp":1641626513000},"page":"e463-e466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4719-7192","authenticated-orcid":false,"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumar","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelonitda","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.01.003_bib0001","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.003_bib0002","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212603","article-title":"Standard care and investigational drugs in the treatment of myelofibrosis","volume":"8","author":"Barraco","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.clml.2022.01.003_bib0003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.01.003_bib0004","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.003_bib0005","unstructured":"Jakafi\u00ae (ruxolitinib) prescribing information. Incyte Corporation, Wilmington, DE. Rev 01\/2020."},{"key":"10.1016\/j.clml.2022.01.003_bib0006","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.003_bib0007","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.003_bib0008","first-page":"1062","article-title":"Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2\/STAT3","volume":"135","author":"Moll\u00e9","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.003_bib0009","doi-asserted-by":"crossref","first-page":"16609","DOI":"10.1038\/s41598-019-53056-x","article-title":"Metabolic Effects of JAK1\/2 Inhibition in Patients with Myeloproliferative Neoplasms","volume":"9","author":"Sapre","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/j.clml.2022.01.003_bib0010","unstructured":"INREBIC\u00ae (fedratinib) prescribing information. Celgene Corporation, Summit, NJ; Rev 08\/2019."},{"key":"10.1016\/j.clml.2022.01.003_bib0011","doi-asserted-by":"crossref","first-page":"14538","DOI":"10.1038\/srep14538","article-title":"Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance","volume":"5","author":"Kesarwani","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2022.01.003_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","article-title":"Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis","volume":"35","author":"Talpaz","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.003_bib0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nchembio.1471","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Ciceri","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.clml.2022.01.003_bib0014","doi-asserted-by":"crossref","first-page":"29-43 e27","DOI":"10.1016\/j.ccell.2018.03.024","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2022.01.003_bib0015","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase II randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.003_bib0016","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.17727","article-title":"Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis","volume":"195","author":"Pardanani","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.003_bib0017","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1097\/HS9.0000000000000553","article-title":"Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial","volume":"5","author":"Mesa","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2022.01.003_bib0018","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1097\/HS9.0000000000000562","article-title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","volume":"5","author":"Harrison","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2022.01.003_bib0019","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.0894-0959.2004.17603.x","article-title":"Serum albumin: relationship to inflammation and nutrition","volume":"17","author":"Don","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.clml.2022.01.003_bib0020","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s00018-016-2133-1","article-title":"Leptin signaling pathways in hypothalamic neurons","volume":"73","author":"Kwon","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clml.2022.01.003_bib0021","first-page":"e27203","article-title":"JAK-STAT in lipid metabolism of adipocytes","volume":"2","author":"Xu","year":"2013","journal-title":"JAKSTAT"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T16:09:27Z","timestamp":1664640567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022000040"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Fedratinib, A Selective Inhibitor of Janus Kinase 2, on Weight and Metabolic Parameters in Patients with Intermediate- or High-risk Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}